In patients with diagnosed AD, the administration of ALA 3 months after a standard treatment with acetylcholinesterase inhibitors showed no significant differences in cognitive scores after a 1-year follow-up [27], but a study from the same group suggested that ALA could promote a slower disease progression rate at a 48-month interval [28]. The gene discussed is ACHE; the disease is Alzheimer disease.